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Childhood cancer is relatively uncommon: in Europe incidence rates range from 140–170 per million 
person-years in children younger than 15 years, and from 180–240 per million in those aged 15–19 
years.1 Their prognosis has substantially improved over recent decades, in part because of the 
assessment and development of their optimal treatment. In this scenario, efforts to improve every 
single step of cancer cure, including diagnostic accuracy, are becoming significant. 
For solid tumors, a correct histopathologic diagnosis is regarded as a cornerstone to implement 
staging and treatment regimen, and hence potentially influencing final patient outcome. In current 
practice, despite the clinical relevance of histology at diagnosis, a degree of discordance in the 
interpretation of morphology or in the integration with ancillary techniques (i.e. 
immunohistochemistry or molecular pathology) still remains even among experienced pathologists, 
above all for rare or complex diseases.2,3 As an example, potentially clinically significant 
discordances have been documented in childhood renal tumors: 39% of anaplastic cases (which 
demand intensified therapies as compared to the other histological subgroups) in the National Wilms 
Tumor Study-5 were not initially recognized by the institutional pathologist, and there were 
discordances in tumor stage in 19% of these cases.4 A similar disagreement between local pathologist 
and secondary specialized review has been recorded in other tumors in both pediatric2,5 and adult3,6,7 
settings. 
Due to their rarity and peculiar characteristics compared to those encountered in adults, tumors in 
children and adolescents should be submitted for prospective rapid central pathology review (CPR) 
by pathologists with sub-specialty expertise in pediatric oncologic pathology to review diagnosis and 
implement tumor staging, especially those registered into clinical trials (CPR is a standardized 
procedure in most clinical protocols). In rare cancers, CPR is even more relevant and may ensures 
consistency in the diagnosis, subclassification, and adequate pathological staging. 
Until recently, in Italy the submission of childhood tumors for CPR was more based on local hospital 




patients had to be registered in controlled clinical trials. In these situations, costs for specimen 
shipment was heterogeneously covered by private financing, ad hoc grants, or local centers resources. 
With experience of previous and ongoing protocols, it became almost expected and ‘accepted’ that 
up to 30% of cases would never be submitted for CPR, undermining the efforts of other health 
professionals who submit their specimens/data. The overall rate of diagnostic discrepancies 
encountered during CPR within the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) 
protocols have never been well assessed. 
Within the AIEOP central committee it has become increasingly recognized that there may be benefits 
from the introduction of a more systematic and nationwide CPR for pediatric tumors throughout 
Italian pediatric oncology centers. Extrapolation of literature data2 has suggested us that in the 
absence of CPR, potentially > 150 patients per year treated at AIEOP institutions (out of 1,500-1,700 
newly diagnosed cases) could receive inappropriate therapy, based on incomplete or inaccurate 
pathologic information.  
AIEOP first identified needs, priorities, and areas for potential improvement in this field (also basing 
on an ad hoc survey addressed to Italian pediatric pathologists), such as increasing the rate of cases 
submitted to reference pathologists for CPR; linking the CPR diagnosis with demographic/clinical 
patient existing records of AIEOP central database; improving feedback communication to treating 
clinicians, especially when diagnostic discrepancies may affect clinical patient management.  
As a first action, in 2016 AIEOP set up a pre-paid shipping system to ease and logistically support 
the submission of pathology specimens from 49 accredited AIEOP centers to 9 centralized reference 
laboratories. 
AIEOP subsequently conceived a central diagnosis review (CDR)-platform linked to the exiting web-
based AIEOP national database for childhood cancer (known as Mod.1.01 form9), based on the IT 
solution AxMR® (Advanced eXtended Multicentre Research) and developed by Cineca (an 




(ISO 27001:2013 certification, https://www.cineca.it/en/content/certifications) and through HTTP 
and SSL protocols encryption standards. 
The CDR-platform provides a secure online database that guarantees compliance to up-to-date high 
security and quality standards and meets all the requirements set by the European General Data 
Protection Regulation.  
Through this approach, the entire data flow concerning histolopatologic review connects to existing 
patient demographic and clinical data (diagnostic, protocol, follow-up) and is based on a patient-
centric approach (Fig. 1): at diagnosis (of a solid childhood cancer or leukemia) every patient is 
registered onto Mod.1.01 once, after obtaining informed consent from parents or guardian, and is 
identified by a Unique Patient Number (UPN). All patient personal data are encrypted for all system 
users except for responsible clinicians (including reference pathologists, who can examine clinical 
information relevant for diagnosis). Through the UPN, the patient can then be assigned to the CDR-
platform and referred for CPR to a given centralized laboratory depending on his/her primary 
diagnosis (the AIEOP pathology working group has agreed upon pathologists of reference for each 
type/family of cancer). The CDR-platform then allows reference pathologists to return their report to 
the responsible clinicians, and linked to all the remaining patient records available in Mod.1.01. Alert 
messages guarantee real-time traceable flow of information, from the referring center to the reference 
laboratory, and forwards. A traffic light system notifies any diagnostic discrepancy, pushing for 
contact between reference pathologists and physicians in charge of the patient care. 
Noteworthy, through integration of reviewed histopathologic diagnosis into comprehensive clinical 
patient data, AIEOP also aims to improve the quality of data itself.  
Routine second review of pathologic material is time consuming, and its value and utility is 
questioned by hospitals. However, pathologic second review could lower overall care costs by 
preventing inappropriate therapy (both over- and under-treatment), especially when pathologists with 




better defined at national level by appropriate regulation/legislative support making CPR mandatory, 
and better defining the terms of responsibility of reviewer and local pathologists, respectively. 
Whether all types of childhood cancers need to be reviewed is debatable. However, since pathologists 
themselves consider pediatric oncology a minefield, especially in countries where specific 
training/specialization on pediatric pathology does not exists, we regard the national review of all 
cases enrolled into protocols for initiation of cure as an important system of quality control and an 
error-reduction strategy.  
 
Recognizing timely obtaining the correct diagnosis and treatment plan critical to the outcome for each 
patient, we hope that in future this project might be supported by the Italian Health Care system as 
other value-based programs. 
The utilization of the system over time will highlight both its strengths and weaknesses, providing 
inputs as to where develop it further. The AIEOP CPR system provides pathologists with a quality of 
practice improvement tool for reporting, documenting and tracking centralized diagnosis. The 
analysis of its use will give us more data about the overall rate of diagnostic discrepancies across 
Italian pediatric cancers or other quality assurance indicators (which will be monitored overtime), 
and thus an estimate of the impact of inappropriate treatment on health care costs.  
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Figure 1. Data flow and access. The cartoon summarizes how the recently introduced Central 
Diagnosis Review (CDR)-system works, and interacts with the existing nationwide database for 
children with cancer (named Mod. 1.01). A) AIEOP centers register each patient with newly 
diagnosed solid tumor or leukemia (identified by a Unique Patient Number, UPN) into Mod. 1.01; B) 
Mod. 1.01 is a prospective database, containing demographic and clinical data, which in turn is linked 
to different disease-specific protocol databases; C) to start a central pathology review (CPR) process, 
AIEOP centers ship pathology specimens to the reference laboratories through a pre-paid courier, 
while launching the request for CPR for a given patient (identified by UPN) through the dedicated 




specimens, and upload the reviewed report on Mod. 1.01 patient unique repository; local centers are 
finally notified when the CPR is complete.       
 
